Long-Term, Open-Label, Safety Study of LY2216684 in Pediatric Patients With Attention Deficit/Hyperactivity Disorder.
Phase of Trial: Phase II/III
Latest Information Update: 01 Oct 2017
At a glance
- Drugs Edivoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Registrational
- Sponsors Eli Lilly
- 18 Aug 2015 Status changed from completed to discontinued as per ClinicalTrials.gov record.
- 14 Aug 2015 Status changed from active not recruiting to completed as per ClinicalTrials.gov record.
- 17 Jul 2015 Planned End Date changed from 1 Dec 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov.